Physician profile
Laura Davis
NPI 1982042735
$5,846.25
in general payments reported to CMS, 2019-2025
36 companies · $877 in 2025
The $877 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $975 · 2021: $793 · 2022: $575 · 2023: $749 · 2024: $845 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,470.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $922.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $748.34 | 2019-2025 | Ofev, Jascayd |
| Lilly USA, LLC | $713.58 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $458.99 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $337.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $331.42 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $317.52 | 2019-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $281.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $258.51 | 2019-2023 | Gardasil 9 |
| Glaxosmithkline, LLC. | $194.92 | 2019-2024 | Trelegy Ellipta, Shingrix, Bexsero |
| Abbvie INC. | $180.15 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $145.43 | 2021-2025 | |
| Pfizer INC. | $139.86 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $119.15 | 2019-2025 | Zoryve |
| Boston Scientific Corporation | $73.31 | 2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.